Local adventitial anti-angiogenic gene therapy reduces growth of vasa-vasorum and in-stent restenosis in WHHL rabbits

Hytönen, Jarkko P

Elsevier BV

Tieteelliset aikakauslehtiartikkelit
© Elsevier Ltd
CC BY-NC-ND https://creativecommons.org/licenses/by-nc-nd/4.0/
http://dx.doi.org/10.1016/j.yjmcc.2018.07.007

https://erepo.uef.fi/handle/123456789/6932
Downloaded from University of Eastern Finland's eRepository
Accepted Manuscript

Local adventitial anti-angiogenic gene therapy reduces growth of vasa-vasorum and in-stent restenosis in WHHL rabbits

Jarkko P. Hytönen, Jouni Taavitsainen, Johannes T.T. Laitinen, Anna Partanen, Kari Alitalo, Olli Leppänen, Seppo Ylä-Herttuala

PII: S0022-2828(18)30404-8
DOI: doi:10.1016/j.yjmcc.2018.07.007
Reference: YJMCC 8760
To appear in: Journal of Molecular and Cellular Cardiology
Received date: 15 January 2018
Revised date: 4 July 2018
Accepted date: 6 July 2018

Please cite this article as: Jarkko P. Hytönen, Jouni Taavitsainen, Johannes T.T. Laitinen, Anna Partanen, Kari Alitalo, Olli Leppänen, Seppo Ylä-Herttuala, Local adventitial anti-angiogenic gene therapy reduces growth of vasa-vasorum and in-stent restenosis in WHHL rabbits. Yjmcc (2018), doi:10.1016/j.yjmcc.2018.07.007

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Local adventitial anti-angiogenic gene therapy reduces growth of vasa-vasorum and in-stent restenosis in WHHL rabbits.

Jarkko P Hytönen*, MD; Jouni Taavitsainen*, MD; Johannes TT Laitinen*, MD; Anna Partanen MD, Kari Alitalo MD, PhD, Olli Leppänen, MD and Seppo Ylä-Herttuala MD, PhD, FESC*

* Authors with equal contribution

a. A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio

b. Translational Cancer Biology Program and Wihuri Research Institute, Biomedicum Helsinki, University of Helsinki, Helsinki


d. Heart Center, Kuopio University Hospital, Kuopio, Finland

e. Gene Therapy Unit, Kuopio University Hospital, Kuopio, Finland

Word count: 5576

Brief title: Inhibition of vasa-vasorum growth attenuates ISR

Corresponding author:

Seppo Ylä-Herttuala, MD, PhD, FESC
Department of Molecular Medicine
A.I. Virtanen Institute, University of Eastern Finland
P.O.Box 1627
FIN-70210, Kuopio
FINLAND
Tel. +358 17 162075
email: Seppo.Ylaherttuala@uef.fi
ABSTRACT

Background

Antiproliferative drugs in drug eluting stents (DES) are associated with complications due to impaired re-endothelialization. Additionally, adventitial neovascularization has been suggested to contribute to in-stent restenosis (ISR). Since Vascular Endothelial Growth Factors (VEGFs) are the key mediators of angiogenesis, we investigated feasibility and efficacy of local gene therapy for ISR utilizing soluble decoy VEGF receptors to reduce biological activity of adventitial VEGFs.

Method

Sixty-nine adult WHHL rabbit aortas were subjected to endothelial denudation. Six weeks later catheter-mediated local intramural infusion of 1.5x10e10 pfu adenoviruses encoding soluble VEGF Receptor-1 (sVEGFR1), sVEGFR2, sVEGFR3 or control LacZ and bare metal stent implantation were performed in the same aortic segment. Marker protein expression was assessed at 6d in LacZ cohort. Immunohistochemistry, morphometrical analyses and angiography were performed at d14, d42 and d90.

Results

Transgene expression was localized to adventitia. All decoy receptors reduced the size of vasa-vasorum at 14d, AdsVEGFR2 animals also had reduced density of adventitial vasa-vasorum, whereas AdsVEGFR3 increased the density of vasa-vasorum. At d42, AdsVEGFR1 and AdsVEGFR2 reduced ISR (15.7±6.9% stenosis, P<0.01 and 16.5±2.7%, P<0.05, respectively) vs. controls (28.3±7.6%). Moreover, AdsVEGFR-3 treatment led to a non-significant trend in the reduction of adventitial lymphatics at all time points and these animals had significantly more advanced neointimal atherosclerosis at 14d and 42d vs. control animals.

Conclusions

Targeting adventitial neovascularization using sVEGFR1 and sVEGFR2 is a novel strategy to reduce ISR. The therapeutic effects dissipate at late follow up following short expression profile of adenoviral vectors. However, inhibition of VEGFR3 signaling accelerates neoatherosclerosis.

KEYWORDS

In-stent restenosis, gene therapy, plaque angiogenesis, re-endothelialization

ABBREVIATIONS

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMS</td>
<td>bare metal stent</td>
</tr>
<tr>
<td>DES</td>
<td>drug eluting stent</td>
</tr>
<tr>
<td>ISR</td>
<td>in-stent restenosis</td>
</tr>
<tr>
<td>VEGF</td>
<td>vascular endothelial growth factor</td>
</tr>
<tr>
<td>VEGFR</td>
<td>vascular endothelial growth factor receptor</td>
</tr>
<tr>
<td>WHHL</td>
<td>Watanabe Heritable Hyperlipidemic</td>
</tr>
</tbody>
</table>
INTRODUCTION

Percutaneous revascularization techniques have revolutionized the treatment of patients suffering from coronary artery disease [1,2]. The introduction of stents prevented elastic recoil and negative remodeling of coronary arteries after angioplasty [3], a key limitation of catheter based treatments until that time. Atherosclerotic disease and mechanical injury caused by the stent itself, however, commonly leads to a new narrowing [4]. This in-stent restenosis (ISR) has been reduced by the discovery of drug eluting stents (DES) [5]. The strong cytotoxic drugs used in DES commonly inhibit ISR, but also delay recovery of the protective endothelial layer leading to prolonged risk of stent thrombosis (ST) and reliance on antithrombotic medication [6].

Plaque angiogenesis has been suggested as one of the major factors in the progression of atherosclerotic lesions [7] and may be driven by hypoxia and energy depletion in macrophage-rich lesion core [8,9]. Intimal and medial cells activate angiogenesis by secretion of several growth factors including Vascular Endothelial Growth Factor A (VEGF-A) [10,11]. This is aggravated by growth factor and cytokine secretion from inflammatory cells, also found in abundance in atherosclerotic lesions. VEGF-A signaling is mediated through VEGFR1 and VEGFR2 with VEGFR1 acting as a decoy receptor as well as transducing weak signals for endothelial growth. VEGFR2 is a key mediator of endothelial cell survival and angiogenesis [12]. VEGF-A signaling leads to the growth of new vasa vasorum from the adventitial layer of the artery. Neoangiogenic capillaries are often poorly organized and leaky, which can lead to small hemorrhages in the growing lesion and to rupture prone, vulnerable plaques [9-11]. While abundant vasa vasorum have been linked to the growth of atherosclerotic lesions [11], and although descriptive studies have reported a correlation between the vasa vasorum density and the percent luminal stenosis after balloon injury [13], the role of plaque angiogenesis in the formation of ISR has remained elusive.
Similarly, the role of lymphangiogenesis and VEGFR3 signaling, the main driver for the growth of lymphatic vessels, is unclear in the ISR formation. In vivo VEGFR3 activation by VEGF-C and VEGF-D triggers the growth of lymphatic vessels. In experimental setting reduced activity of VEGF-C has been shown to elevate cholesterol levels and accelerate atherogenesis [14]. However, the effects of lymphangiogenesis and lymphatic structures on ISR are unknown.

We studied the effects of anti-angiogenic therapy on the development of ISR in a clinically relevant triple injury model [15]. Adenoviruses encoding soluble decoy receptors (sVEGFR) 1, 2 and 3 or control LacZ were infused intramurally into the vascular wall at the time of stenting. Analyses of the control animals at 6d demonstrated the marker protein expression in the outer layers of media and in the adventitia. sVEGFRs expressed by cells in the abluminal vessel layers act as secreted decoy receptors and bind to VEGFs, thus limiting their biological activity and reducing angiogenesis and lymphangiogenesis [16]. We hypothesized that adventitial sVEGFR overexpression would lead to attenuated angiogenesis or vasa vasorum growth and ultimately have an effect on in-stent restenosis.
METHODS

Adenoviruses

Replication-deficient E1-partially E3-deleted clinical GMP-grade adenoviruses encoding nuclear-targeted β-galactosidase (LacZ) or soluble VEGF receptors 1, 2 and 3 were produced and tested to be free of contaminants [17]. The same adenoviral constructs have been studied previously and shown to produce transgene products and be biologically active in vivo [18].

Animal model

Animal experiments were approved by the University of Eastern Finland Research Ethics Committee and conforms to the National Institutes of Health guidelines. Adult (six month old) Watanable Heritable Hyperlipidemic (WHHL) rabbits (n=69), with mutated LDL receptor gene resulting in high circulating cholesterol levels [15], were randomized into study groups. The aortas of the animals were denuded of endothelium via the right femoral artery with three passes of inflated 3F embolectomy catheter (Fogarty arterial embolectomy catheter, Edwards Lifesciences) under ketamine (15 mg/kg, Ketalar, Pfizer) and medetomidine (0.3 mg/kg, Domitor, Orion Pharma) anesthesia [15]. Denudation was performed between the level of the renal arteries and aortic bifurcation. Six weeks after the denudation the rabbits were anesthetized again and a 6F introducer sheath (Avanti+, Cordis) was placed into the right carotid artery exposed through a mid-line incision. A guiding catheter (Vista Brite Tip, Cordis) and a guide wire (Stabilizer, Cordis) were advanced to the descending aorta under fluoroscopic guidance (GE Innova 3100IQ, GE Healthcare). Angiography was performed, the guiding catheter removed and Infiltrator® (IVT, Boston Scientific) drug delivery catheter advanced to the aorta. A segment in the distal parts of the aorta free of side branches was selected. The drug delivery catheter was moved to the selected segment and inflated according to manufacturer’s instructions. Two mL of diluted virus solution with 1.5 x 10e10 pfu of either AdLacZ, AdsVEGFR1, AdsVEGFR2 or AdsVEGFR3 was infused through the
0.01” high injection needles of the catheter over two minutes. The catheter was deflated and replaced with a straight guiding catheter and a bare metal stent (3.5x18mm, Multi-Link Zeta, Abbott Vascular) was deployed. The stent was positioned over the gene transfer site and inflated to accommodate the vessel in an approximately 1:1 ratio. Angiography was repeated to confirm appropriate stent placement (Figure 1). Angiography was repeated before sacrifice 14, 42 or 90 days after the stent implantation. An additional cohort receiving AdLacZ was sacrificed six days after the gene transfer to document gene transfer efficacy and assess the distribution of transgene expression. At the end of the follow up, the animals were sacrificed with a large i.v. bolus of saturated MgSO₄ under general anesthesia and the vasculature was perfused with PBS. The stented segment of the aorta was fixed with paraformaldehyde and mounted in methacrylate and processed further for histopathological analyses [15]. Tissue samples from the heart, lung, liver, spleen, kidney and skeletal muscle were harvested for general histology and biodistribution analyses and were embedded into paraffin blocks after tissue fixation and dehydration. Segments of aorta from the edges of the stent were processed through paraffin histology and stained for β-galactosidase from d6 animals.

Histology

Stents were segmentally cut into ≤7 µm serial sections and stained with hematoxylin and eosin as well as Van Gieson stain for elastin [15]. Immunohistological stains were performed with antibodies against endothelial cells (CD31, DAKO), lymphatic endothelium (LYVE-1, DAKO), rabbit macrophages (RAM-11, DAKO), proliferating cells (Ki-67, DAKO), β-galactosidase (Promega) and smooth muscle cell actin (HHF-35, Enzo). Following treatment with the primary antibody samples were incubated with a biotinylated secondary antibody followed by avidin-biotin complex. Visualization was achieved with the DAB peroxidase system (Vector Laboratories). All immunohistological stainings were performed with hematoxylin counterstaining. Analyses were performed from all stents from a single layer along the stent. Images were acquired with Olympus.
AX70 microscope (Olympus Optical) and quantitative analyses performed with AnalySIS software (Soft Imaging System).

Adventitial vessels were quantified from CD31 stained sections. CD31 positive vessels were counted and their cross-sectional area measured from the adventitia [15,19]. The number of vessels is expressed as number of vessels per mm$^2$ of tissue. Similar measurements were carried out for lymphatic vessels from LYVE-1 stained samples [14]. Endothelialization was determined from CD31 stained sections as the percentage of luminal circumference covered by CD31 positive cells.

Proliferating cell nuclei were identified in the neointima from Ki-67 staining. Data is expressed as the number of cells per mm$^2$ of neointima. Areas identified from RAM-11 staining containing macrophages were outlined and data is shown as macrophage density in the neointima [20].

The stented aortic segments were further characterized by determining the injury score [21] and evaluating the severity and type of the atherosclerotic changes. The severity of atherosclerotic changes in neointima was assessed and a grade between I-VI [22,23] was assigned. Briefly, type I lesions show isolated foam cells, type II have fatty streaks with intracellular lipid accumulation, type III includes extracellular lipid pools, type IV lesion with a core of extracellular lipid, type V or fibroatheroma has a lipid core with a fibrotic layer and type VI shows characteristics of complicated lesions with possible thrombus or hemorrhagic changes. Degree of restenosis was determined from cross-sectional HE stained images as ratio of neointimal area to internal elastic lamina area \( ([1-(\text{Luminal area}/\text{IEL area}) \times 100]) \).

Blood chemistry

Blood drawn from the animals before treatment and at sacrifice were analyzed for lipid profile and signs of toxicity and included measurements for ALT, ALP, Creatinine, total cholesterol, HDL, LDL, triglycerides and urea. All analyses were done at a dedicated veterinary clinical chemistry laboratory (Movet, Kuopio, Finland).
Statistical analysis

All results were analyzed for statistical significance using one-way ANOVA with Dunnet’s post hoc test with GraphPad Prism 6 software (GraphPad Software, La Jolla, CA, USA). P values less than 0.05 were considered significant. All data are expressed as mean ± SD.

RESULTS

Gene transfer

Marker gene expression was confirmed in LacZ treated aortas at six days after the gene transfer. β-galactosidase positive cells were detected in the connective tissue of the adventitia, mainly in fibroblasts. Positive cells were also seen in the liver surrounding the sinusoids and the spleen, but not in other collected tissue samples (Figure 2) following AdLacZ gene transfer.

Adventitial vasa vasorum

Treatment with AdsVEGFR1 and AdsVEGFR2 led to a decrease in the size of adventitial vessels 14d after the stenting (158.3±28.6µm², 134.2±48.7µm² and 212.4±24.6µm² for AdsVEGFR1, AdsVEGFR2 and AdLacZ respectively; P<0.05 AdsVEGFR1, P<0.01 for AdsVEGFR2) (Figure 3). AdsVEGFR3 treatment resulted in an even greater (59.5µm²±11.6, P<0.001) reduction in the average size of vasa vasorum compared to AdLacZ. At d14, the density of capillaries was reduced in the AdsVEGFR2 treated animals whereas the treatment with AdsVEGFR3 resulted in a marked increase in the density of adventitial vasa vasorum (20.2±11.6, 609.9±107.7 and 162.4±46.6 vessels per mm² for AdsVEGFR2, AdsVEGFR3 and AdLacZ, respectively; P<0.01 for AdsVEGFR2 and P<0.001 for AdsVEGFR3) (Table 1). There were no significant differences at later time points of 42 and 90 days (Figure 3).
Luminal endothelialization

No differences were observed in the rate of luminal re-endothelialization. The endothelial layer had recovered moderately in all groups by two weeks. None of the groups showed complete endothelialization even at the three-month follow-up (Table 1).

In-stent restenosis

The ISR calculated as the percentage narrowing of the stented lumen was significantly decreased in the AdsVEGFR1 and AdsVEGFR2 treated groups compared to controls 42d after stenting (15.7±6.9, 16.5±2.7 and 28.3±7.6 percent restenosis for AdsVEGFR1, AdsVEGFR2 and AdLacZ, respectively; P<0.01 for AdsVEGFR1 and P<0.05 for AdsVEGFR2) (Figure 4). No significant differences were observed at other time points or treatment with AdsVEGFR3 (Table 1).

Macrophage infiltration and lesion characteristics

Moderate macrophage infiltration was seen in all groups. The macrophage density was generally greater in areas surrounding the stent struts (Figure 5). No differences were observed between the groups (Table 1).

The in-stent neointimal lesions displayed more advanced atherosclerotic changes at d14 in AdsVEGFR3 treated arteries compared to control with a score of 3.7±0.6 vs. 2.4±0.8 in AdLacZ, P<0.05 (2.8±0.8 and 2.3±0.5 for AdsVEGFR1 and AdsVEGFR2, respectively, P=NS) (Figure 5). The same was also seen at d42 with AdsVEGFR3 treated rabbits with a score of 4.0±1.0 vs. 2.5±1.0 in AdLacZ, P<0.05 (2.7±0.8 and 2.6±0.5 for AdsVEGFR1 and AdsVEGFR2, respectively, P=NS). There were no significant differences at d90.

Adventitial lymphatic vessels
Treatment with sVEGFR3 resulted in a trend towards reduced number of LYVE-1 positive lymphatic vessels in the adventitia at all time-points although the difference was not statistically significant (Figure 6). Gene transfers with other sVEGFRs did not influence the growth of lymphatic vessels (Table 1).

Neointimal proliferation

No statistically significant differences were observed in the number of proliferating cells in the neointima in any of the time points. At d14 proliferation counts were 62.2±27.2, 58.2±15.1, 58.1±23.4 and 43.3±23.8 per square mm of neointima for AdLacZ, AdsVEGFR1, AdsVEGFR2 and AdsVEGFR3, respectively. Number of proliferating cells was reduced in all groups at d42 with 4.6±1.5, 4.1±4.6, 6.1±3.0 and 3.5±3.3 for AdLacZ, AdsVEGFR1, AdsVEGFR2 and AdsVEGFR3, respectively, P=NS. Proliferation rates at d90 were 11.5±5.6, 14.5±6.5, 9.9±3.7 and 10.2±4.3 for AdLacZ, AdsVEGFR1, AdsVEGFR2 and AdsVEGFR3, respectively, P=NS.

Blood chemistry and safety analyses

No signs of toxicity or side effects were found based on clinical chemistry (Table 2) and histopathological analysis of the major organs (Supplementary Figures 1-5). There were no differences between the groups in local inflammatory responses, neointimal proliferation or injury scores (Table 1).

DISCUSSION

The role of vasa vasorum in the formation of primary atherosclerotic lesions has previously been suggested [11]. In this study we show that by blocking angiogenic signaling using adventitial expression of decoy receptors for VEGFR1 or VEGFR2 reduces the number and size of adventitial vasa vasorum, and leads to reduction of ISR. Conversely, periadventitial targeting of prolymphangiogenic VEGFR3 activation with decoy inhibitors resulted in a more adverse in-stent
neointimal atherosclerotic phenotype. We utilized an atherosclerotic model in which a lesion is created in a hypercholesterolemic animal with additional balloon injury prior to the stenting procedure to mimic the clinical setting of coronary stenting. Time-points were selected to address the acute changes after peak transgene expression at d14, the subacute changes in restenosis formation at d42 and chronic lesion development at d90. Use of the intermediate d42 time-point is well documented in prior literature [23,24]. Limitations of the study are the lack of a solvent group with injections lacking viral particles and a stent group without drug delivery catheter intervention.

Treatment with AdsVEGFR1 and AdsVEGFR2 resulted in an attenuated adventitial angiogenic response two weeks after the treatment, following the peak transgene expression of adenovirus vector system [26]. Possibly due to the limited duration of expression of adenoviruses, the effect on the vasa vasorum size and density was lost at the later time points. The main angiogenic signaling occurs via the VEGFR2 pathway whereas the VEGFR1 acts partly as a decoy receptor in the physiological setting [12]. In this study, treatment with AdsVEGFR2 resulted in both fewer and smaller adventitial vessels while AdsVEGFR1 treatment only affected the size of vasa-vasorum suggesting that targeting VEGFR2 pathway might be the most potent approach for the inhibition of the growth of vasa vasorum. However, both AdsVEGFR1 and AdsVEGFR2 treatments resulted in similar reductions in ISR at six weeks follow up.

Following the impaired adventitial angiogenesis at two weeks, both the AdsVEGFR1 and AdsVEGFR2 treated animals showed a reduction in ISR six weeks after the treatment. The reduced angiogenesis seen at the two-week time point likely contributes to the reduced ISR four weeks later. In fact it has been shown that the adventitial tissue surrounding arterial stents is hypoxic in nature and this hypoxia leads to the growth of adventitial vessels, this adventitial angiogenesis is reduced by AdsVEGFR1 and AdsVEGFR2 therapy in this study [27]. Interestingly, a similar degree of reduction in ISR was seen with AdsVEGFR1 although its effects on vasa-vasorum at d14 were more limited compared to AdsVEGFR2 therapy. The results are in line with previous findings
showing increased neointima formation in rabbit carotid arteries following adventitial VEGF gene transfers [28]. Similar to the loss of the anti-angiogenic effect, no effects on ISR were observed at the extended follow-up of 90 days. The transient therapeutic effects suggests that an alternative vector system or other delivery method should be considered in the future to accomplish more sustained reduction in ISR.

The in-stent neointima formation observed already at the two-week time-point represents more than half of the ISR seen at the extended follow-up of 90d in all treatment groups. This finding confirms that the acute phase of 1-2 weeks after the stent placement is critical for the healing process of the artery and the onset of ISR [29]. While a drug eluting stent will potentially start the release of therapeutic agent immediately after stent implantation, all gene therapy based approaches have the limitation of delayed onset of therapy as the therapeutic protein will only be produced after sufficient transduction of the transgene.

The rate of regeneration of the luminal endothelium was similar in all groups at all time points and was not influenced by the transient adventitial expression of anti-angiogenic decoy receptors. Physiological VEGF signaling maintains endothelial homeostasis [30] and is necessary for endothelial recovery after stenting. The adventitial expression in this study seems to limit therapeutic effects of the soluble receptor proteins mainly to the adventitia and enables paracrine actions of the decoy inhibitors thus allowing the luminal endothelium to regenerate to the same extent in the treated and control arteries. The lack of complete re-endothelialization even at d90 confirms the clinical relevance of the WHHL rabbit model used in this study mimicking severe atherosclerosis and chronic endothelial dysfunction present in patients with occlusive arterial disease. No signs of toxicity or adverse effects were observed.

Treatment with AdsVEGFR3 also seemed to alter angiogenesis in the stented artery. At two weeks AdsVEGFR3 treated animals displayed a marked increase in the capillary density around stented
vessel segments while the average size of the new vessels remained notably small. This effect on angiogenesis did not alter ISR at the intermediate time point of d42 unlike the treatments with AdsVEGFR1 and AdsVEGFR2. Reduction of VEGFR3 signaling has been shown to interfere with Notch signaling resulting in a hypervascular phenotype of angiogenesis with increased sprouting [31]. It is possible that AdsVEGFR3 administered here has had a similar effect on the adventitial vasculature. Treatment with AdsVEGFR3 also resulted in a statistically non-significant trend towards blockage of lymphangiogenesis at all time points.

Treatment with AdsVEGFR3 led to an altered composition of the developing neointima, which was observed already at d14 (Fig 5). AdsVEGFR3 treated arteries showed more complicated neointimal changes with higher atherosclerotic lesion scores [20,21]. Increased VEGFR3 signaling with periluminal delivery of AdVEGF-C has in the past been shown to limit intimal thickening following balloon angioplasty in a rabbit model [32]. Here we show more complicated neointimal lesions with an intervention that reduces periadventitial VEGFR3 activation following stent placement in atherosclerotic arteries. Local lymphatics have been suggested to contribute to the drainage of interstitial fluid and cholesterol from the atherosclerotic arterial wall [14,33]. Taken together, local activation of VEGFR3 may present a new possibility to treat restenotic arterial disease and promote healing after stent implantation.

**CONCLUSIONS**

This study suggests that adventitial plaque angiogenesis plays an important role in the pathogenesis of ISR. Importantly, the abluminal delivery of anti-angiogenic agents reduced ISR but did not affect the regeneration of luminal endothelium. Conversely, periadventitial inhibition of lymphangiogenic signaling adversely influenced healing after stent implantation. Therefore, local gene therapy is a potential new way to reduce adventitial angiogenesis and ISR in patients who require angioplasty and stent placement.
DISCLOSURES

None.

ACKNOWLEDGEMENTS
This study was supported by the Academy of Finland Centres of Excellence, Finnish Foundation for Cardiovascular Diseases, Sigrid Juselius foundation, Aarne Koskelo foundation, The Finnish Medical Foundation, Päivikki and Sakari Sohlberg Foundation and the Finnish Cultural Foundation.
REFERENCES


Table 1. Histological analyses.

<table>
<thead>
<tr>
<th>Number of animals (n)</th>
<th>Number of animals (n)</th>
<th>Number of animals (n)</th>
<th>Number of animals (n)</th>
<th>Number of animals (n)</th>
<th>Number of animals (n)</th>
<th>Number of animals (n)</th>
<th>Number of animals (n)</th>
<th>Number of animals (n)</th>
<th>Number of animals (n)</th>
<th>Number of animals (n)</th>
<th>Number of animals (n)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>AdsVE GFR1</td>
<td>AdsVE GFR2</td>
<td>AdsVE GFR3</td>
<td>AdL acZ</td>
<td>AdsVE GFR1</td>
<td>AdsVE GFR2</td>
<td>AdsVE GFR3</td>
<td>AdL acZ</td>
<td>AdsVE GFR1</td>
<td>AdsVE GFR2</td>
<td>AdsVE GFR3</td>
</tr>
<tr>
<td>Vasa-vasorum density</td>
<td>163.9±5</td>
<td>20.2±11.6 **</td>
<td>69.9±11.6 **</td>
<td>162.4±6.6</td>
<td>201.1±6.6</td>
<td>148.2±10.0</td>
<td>10.0</td>
<td>406.1±11.1</td>
<td>11.1</td>
<td>263.1±13.7</td>
<td>57.8±7.7</td>
</tr>
<tr>
<td>(vessels/mm²)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vasa-vasorum size</td>
<td>158.3±2.8</td>
<td>134.3±2.8</td>
<td>59.7±11.6</td>
<td>212.4±24.6</td>
<td>185.7±9.5</td>
<td>195.1±14.4</td>
<td>90.2±42.9</td>
<td>141.2±39.6</td>
<td>111.2±54.3</td>
<td>115.7±33.5</td>
<td>151.4±66.4</td>
</tr>
<tr>
<td>(average size/um²)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>In-stent restenosis</td>
<td>39.7±2.8</td>
<td>14.6±3.0</td>
<td>21.7±2.2</td>
<td>16.2±5.2</td>
<td>15.7±6.9</td>
<td>16.5±2.7</td>
<td>28.9±6.8</td>
<td>25.7±15.5</td>
<td>25.7±15.5</td>
<td>25.7±15.5</td>
<td>25.7±15.5</td>
</tr>
<tr>
<td>(luminal narrowing/%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Luminal endothelium</td>
<td>61.3±5.3</td>
<td>47.4±5.6</td>
<td>46.7±2.2</td>
<td>57.5±41.5</td>
<td>91.4±16.7</td>
<td>85.8±16.8</td>
<td>53.4±31.5</td>
<td>78.1±1.5</td>
<td>83.5±11.8</td>
<td>69.4±22.0</td>
<td>79.0±10.6</td>
</tr>
<tr>
<td>(endothelial coverage/%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neointimal macrophages</td>
<td>36.2±8.8</td>
<td>9.7±11.5</td>
<td>23.7±11.6</td>
<td>17.4±12.7</td>
<td>16.8±9.7</td>
<td>17.8±9.6</td>
<td>24.8±14.7</td>
<td>13.9±5.8</td>
<td>23±7±13.7</td>
<td>21.4±16.1</td>
<td>21.0±13.8</td>
</tr>
<tr>
<td>(area covered by macrophages/%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Injury score</td>
<td>0.3±0.4</td>
<td>0.5±0.3</td>
<td>0.3±0.2</td>
<td>0.6±0.3</td>
<td>0.4±0.3</td>
<td>0.7±0.3</td>
<td>0.4±0.3</td>
<td>0.5±0.3</td>
<td>0.2±0.1</td>
<td>0.4±0.1</td>
<td>0.6±0.3</td>
</tr>
<tr>
<td>(mechanical injury 0-3)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lymphatics density</td>
<td>7.5±5.0</td>
<td>5.1±4.5</td>
<td>5.0±5.2</td>
<td>2.9±3.4</td>
<td>3.5±1.7</td>
<td>3.3±0.5</td>
<td>0.6±0.3</td>
<td>4.3±5.2</td>
<td>1.6±2.0</td>
<td>3.8±5.9</td>
<td>0.2±0.1</td>
</tr>
<tr>
<td>(vessels/mm²)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lesion characterization</td>
<td>2.8±0.8</td>
<td>2.3±0.5</td>
<td>3.7±0.6*</td>
<td>2.4±0.8</td>
<td>2.7±0.8</td>
<td>2.6±0.5</td>
<td>4.0±1.0*</td>
<td>2.5±1.0</td>
<td>0.3±0.5</td>
<td>3.8±1.2</td>
<td>3.2±1.0</td>
</tr>
<tr>
<td>(atherosclerotic severity score 1-6)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Results of various assessments of stent histology. Injury score determined for each strut (0-3) and averaged for the stent. Statistical significance represented with *<0.05, **<0.01, ***<0.001.

Comparisons are made to AdLacZ treated animals.
### Table 2. Blood chemistry.

<table>
<thead>
<tr>
<th></th>
<th>d14</th>
<th>d42</th>
<th>d90</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>AdLacZ</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALT (mmol/l)</td>
<td>46.9±17.8</td>
<td>61.1±1.0</td>
<td>51.6±27.8</td>
</tr>
<tr>
<td>ALP (mmol/l)</td>
<td>33.4±9.5</td>
<td>48.4±15.1</td>
<td>44.4±11.8</td>
</tr>
<tr>
<td>Creatinine (mmol/l)</td>
<td>76.6±15.2</td>
<td>73.3±12.5</td>
<td>68.8±19.9</td>
</tr>
<tr>
<td>Cholesterol (mmol/l)</td>
<td>17.4±4.8</td>
<td>19.2±4.2</td>
<td>17.9±2.1</td>
</tr>
<tr>
<td>HDL (mmol/l)</td>
<td>0.7±0.2</td>
<td>0.7±0.1</td>
<td>0.7±0.1</td>
</tr>
<tr>
<td>LDL (mmol/l)</td>
<td>16.6±5.8</td>
<td>18.8±3.8</td>
<td>17.1±0.7</td>
</tr>
<tr>
<td>Triglycerides (mmol/l)</td>
<td>4.0±0.8</td>
<td>5.5±3.5</td>
<td>4.9±5.4</td>
</tr>
<tr>
<td>Urea (mmol/l)</td>
<td>6.3±1.5</td>
<td>6.5±0.7</td>
<td>6.2±0.6</td>
</tr>
</tbody>
</table>

Blood chemistry analyses. No differences were found between the groups and no clinical or laboratory signs of systemic toxicity were observed. ALT = alanine transaminase, ALP = alkaline phosphatase, HDL = high density lipoprotein, LDL = low density lipoprotein, Cholesterol indicates total serum cholesterol. Data shown as mean ± SD. Comparisons are made to AdLacZ treated animals.
Figure 1. Stent implantation

Pre-stenting angiogram (a) was performed to visualize the abdominal aorta and aortic bifurcation (arrow). Stent was deployed after gene transfer to a segment free of side branches (b, arrowheads mark the radio-opaque markers of the catheter). Post-stenting angiogram was performed (c) to confirm adequate stent placement and to exclude dissection or thromboembolic complications (stent marked with arrowheads). Insert in b shows an inflated drug delivery balloon.

Figure 2. Marker gene expression.

Immunohistology from AdLacZ treated stent six days after gene transfer and stenting with β-galactosidase staining. Positive cells are seen in the adventitia of the stented segments (a and b, higher magnification from indicated area shown in b) as well as arterial segments at the edges of the stent (c and d, higher magnification in d) (dark brown staining). Positive staining is also seen in the spleen (e) and liver (f) six days after treatment. Magnification 40x for a and c, 100x for e and f, 200x for b and d. Scale bars 100µm. Arrows in b, d, and f indicate positive cells.

Figure 3. Adventitial angiogenesis.

AdsVEGFR1 resulted in a reduction in the average size of vasa-vasorum vessels two weeks after the treatment with no effect on the density of adventitial capillaries (a, e). AdsVEGFR2 treated arteries showed smaller and fewer adventitial vessels (b, f) than control LacZ. Gene transfer with AdsVEGFR3 resulted in a dense vasa-vasorum network of small vessels (c, g) compared to control group (d, h). There were no differences in the average cross-sectional size (i) or density (j) of vasa-vasorum at the later time points of d42 or d90. Immunohistological images (a-h) with CD31 antibody staining for endothelium (dark brown) showing capillaries in the adventitia (arrowheads). Scale bars 100µm. P values are *<0.05, **<0.01, ***<0.001. Box-whisker plots with median, 1st and
3rd quartiles and minimum and maximum values. Comparisons are made to AdLacZ treated animals.

**Figure 4. In-stent restenosis.**

Six weeks (d42) after gene transfer a reduction of ISR was seen with AdsVEGFR1 (a-b) and AdsVEGFR2 (c-d). AdsVEGFR3 group (e-f) did not differ from AdLacZ (g-h). No differences were seen in restenosis at the d14 or d90 time points (i). Histological stains with elastic stain (a-h) where the internal elastic lamina (IEL) and external elastic lamina (EEL) are clearly visualized. Histological images on the right are higher magnification of images on the left. Scale bars 100µm in a-h. P values *<0.05, **<0.01. Box-whisker plots with median, 1st and 3rd quartiles and minimum and maximum values. Comparisons are made to AdLacZ treated animals.

**Figure 5. Neointimal macrophages**

There were no differences in the abundance of macrophages between the study groups at any time points. Most macrophages were found near the stent struts. At d14 the neointima of AdsVEGFR3 treated animals (c) had a more severe atherosclerotic lesion phenotype compared with AdsVEGFR1 (a), AdsVEGFR2 (b) or control AdLacZ (d). A similar effect was observed at d42 (e-h) but no significant differences were seen at the extended time point of d90 (i-l). Grading of lesion characteristics (m), the size of macrophage-populated neointimal area (n) and injury score (o) are presented. 200x magnification of RAM-11 immunohistological staining for macrophages (a-l). Scale bars 100µm. P values *<0.05. Box-whisker plots with median, 1st and 3rd quartiles and minimum and maximum values. Comparisons are made to AdLacZ treated animals.
Figure 6. Adventitial lymphatics

Representative images of LYVE-1 positive adventitial lymphatic vessels (arrows) at d42 (a-d) 200x magnification. Density of adventitial lymphatic vessels of AdsVEGFR3 treated arteries were consistently low at all time points (e) although the difference was not statistically significant vs. control group. Scale bars 100μm. Box-whisker plots with median, 1st and 3rd quartiles and minimum and maximum values. Comparisons are made to AdLacZ treated animals.

Supplementary Figure 1.
CD31 and Ki-67 stainings for myocardium from samples collected at d14, d42 and d90 time-points. Magnifications 100x.

Supplementary Figure 2.
CD31 and Ki-67 stainings for lungs from samples collected at d14, d42 and d90 time-points. Magnifications 100x.

Supplementary Figure 3.
CD31 and Ki-67 stainings for kidneys from samples collected at d14, d42 and d90 time-points. Magnifications 100x.

Supplementary Figure 4.
CD31 and Ki-67 stainings for liver from samples collected at d14, d42 and d90 time-points. Magnifications 100x.

Supplementary Figure 5.
CD31 and Ki-67 stainings for spleen from samples collected at d14, d42 and d90 time-points. Magnifications 100x.
Highlights:

- Complex atherosclerotic lesions are associated with increased vasa vasorum growth
- Role of adventitial vasa vasorum after stenting has not been previously studied
- Adventitial antiangiogenic gene therapy reduces vasa vasorum growth
- Attenuated vasa vasorum growth is followed by reduced in-stent restenosis
Figure 2
Figure 5
Figure 6
Figure 7

### Myocardium

<table>
<thead>
<tr>
<th></th>
<th>d14</th>
<th>d42</th>
<th>d90</th>
</tr>
</thead>
<tbody>
<tr>
<td>LacZ</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>sVEGFR1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>sVEGFR2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>sVEGFR3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD31</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ki-67</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Figure 9

<table>
<thead>
<tr>
<th></th>
<th>d14</th>
<th>d42</th>
<th>d90</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kidney</td>
<td>LacZ</td>
<td>sVEGFR1</td>
<td>sVEGFR2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD31</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ki-67</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Figure 9
<table>
<thead>
<tr>
<th></th>
<th>d14</th>
<th>d42</th>
<th>d90</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liver</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD31</td>
<td>LacZ</td>
<td>sVEGFR1</td>
<td>sVEGFR2</td>
</tr>
<tr>
<td>Ki-67</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Figure 10